The Journal of Clinical Investigation (Li, D., et al.) 11.14.2023, published “Spliceosome malfunction causes neurodevelopmental disorders with overlapping features.” The article discusses neurodevelopmental disorders arise during childhood (NDDs), a diverse group including autism spectrum disorder and intellectual disability.
This Research/Other Pub section includes peer-reviewed articles on cutting edge research or on existing research to either substantiate it or question its findings. Peer-reviewed articles are those in which a panel of experts in the same fields as the authors reviews the articles prior to publication to ensure scientific quality. This section also includes other publications which are not peer-reviewed.
The LDA is providing the articles in this section for your information. The articles included express the findings and opinions of the authors and are not necessarily those of the the LDA.
eBioMedicine (Vrijmoeth, H.D., et al.) 11.27.2023 published “Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study.” In this study, researchers assessed 1135 physician-confirmed Lyme disease patients from the time of initiation of treatment with antibiotics to a one year follow-up. Findings showed that the determinants of persistent symptoms after Lyme disease infections and initial treatment were considered “mainly generic.” Determinants of 295 patients with persistent symptoms included a baseline of physical and social functioning that was poorer, depression and anxiety scores that were higher, illness perceptions that were more negative, as well as having baseline comorbidities, fatigue, cognitive impairment, and pain.
The People’s Pharmacy, Joe Graedon, (11.28.2023) reports “New Concerns About Gabapentin and Pregabalin (Lyrica) for Nerve Pain.” Concerning data has come out of the FDA’s Adverse Event Reporting System (FAERS) regarding drugs that are regularly prescribed for nerve pain.
Frontiers (Alruwaili, Y., et al.) 11.21.2023, published “Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease.” This article delves into Lyme disease caused by Borrelia burgdorferi, a prevalent tick-borne infection in North America. While most cases are treatable with antibiotics, a subset of patients experiences chronic symptoms known as […]
The Journal of Pediatric Ophthalmology & Strabismus (Silverstein M., et al.) 10.25.2023, published “Yearly Occurrence and Seasonality of Neuro-ophthalmic Manifestations of Pediatric Lyme Disease.” This article reviews the manifestation of visual problems related to the nervous system in relation to Lyme disease in at a central Ohio pediatric tertiary care center.
5 On Your Side (Bassler, H.) 11.22.2023, published “A sesame seed-sized tick is spreading across Missouri. Here’s what to know.” The article discusses the spread of various tick-borne diseases in Missouri, particularly due to the invasive Asian longhorned tick. This tick was first reported in the U.S. in 2017, but potentially present since before 2010. It has been detected across multiple states and is known for transmitting diseases like anaplasmosis, babesiosis, ehrlichiosis, […]
The Oxford University Press (McGowan, M. S., et al.) 10.24.2023, published “Acute Lyme Disease With Atypical Features due to Borrelia mayonii.” This article discusses the emergence of a new strain of Lyme disease called Borrelia mayonii and its limited impact since its identification in the US in 2016. Only a few cases have been reported, emphasizing the need for increased awareness.
JAMA Network (Vordenberg, S. E.) published on 11.03.2023 an article, “Topical Nonprescription Pain Medications for Adults.” In this article post, Vordenberg talks about nonprescription pain medications that you can buy without a prescription. These medications are applied directly to the skin to relieve pain.
Topical Nonprescription Pain Medications are pain-relieving drugs that you can buy without a prescription and are applied on the skin, making them easy to use. They work by effectively treating pain from various conditions, both short-term and long-term. Since they are applied on the skin, they are less likely to cause side effects or interact with other medications compared to pills. Pain relief usually starts within a few days of using them.
Courthouse News Service (Langford, C.) 11.16.2023, published “Fifth Circuit rejects Lyme disease patients’ coverage-denial conspiracy claims.” The article discusses the ruling of a legal case where patients with long-term Lyme disease were denied coverage and sued the Infectious Diseases Society of America (IDSA) for their stance on chronic Lyme disease. The patients alleged that the IDSA conspired with health insurers to establish guidelines that limited treatment for Lyme disease […]
Frontiers (Stewart Z., et al.) 10.24.2023, published “Crowd-sourced investigation of a potential relationship between Bartonella-associated cutaneous lesions and neuropsychiatric symptoms.” This article explores the potential relationship between Bartonella bacteria infections and psychiatric symptoms, focusing on how certain skin lesions associated with Bartonella might coincide with neuropsychiatric issues.